by The Spanish National Cancer Research Centre

edited by Gaby Clark, reviewed by Robert Egan

Editors' notes

The GIST

Add as preferred source

Intronic sgMYCN induces locus-specific DNA damage response and potentiates doxorubicin response. Credit: Molecular Cancer (2025). DOI: 10.1186/s12943-025-02542-0

The onset and aggressiveness of cancer are related to the abnormal behavior of certain genes, known as oncogenes. The best-known of these alterations is mutation, but it is not the only one. Sometimes, within a cell, a very high number of copies of the oncogene appear—tens or even hundreds. This amplification of oncogenes occurs in a significant proportion of solid tumors and may make the tumor more aggressive and prevent the body's defenses from detecting it, contributing to the development of resistance to treatments.

A study led by Sandra Rodríguez-Perales, head of the Molecular Cytogenetics and Cancer Genome Editing Unit at the Spanish National Cancer Research Centre (CNIO), and by Raúl Torres, from the Innovative Therapies Unit at CIEMAT, uses the amplification of oncogenes as a vulnerability to fight the tumor.

Published in Molecular Cancer, the study offers proof of concept in animal models to destroy tumor cells containing amplified oncogenes through gene editing. Thus, the excess copies of the oncogene become a tumor's Achilles' heel.

Cutting to the root of the problem: The oncogene

"We used the CRISPR-Cas9 gene editing tool to make a cut in the amplified oncogene. Normally, when a cell detects damage in its DNA, it repairs it; but if the gene is amplified and exists in multiple copies, the cut occurs in all of them and a high level of genetic damage builds up. As it lacks the capacity to fully repair it, the cell triggers its cell death machinery," Rodríguez explains.

The gene editing mechanism also affects healthy cells, but since they do not have the amplified gene, they can repair the cuts made.

"This addresses one of the major bottlenecks in gene editing therapies: achieving selective cutting, so that it targets tumor cells [in this case, those with amplified oncogenes] without harming healthy cells," the authors state.

The new strategy has been tested in cellular and animal models of neuroblastoma, small cell lung cancer and colon cancer. These experiments saw a reduction in tumor growth, an increase in animal survival, and changes that may indicate a tumor-fighting immune response.

Teaching the immune system

Cell death would be induced by high levels of damage to the DNA. The team's hypothesis is that this type of cell death could alert the immune cells and promote the activation of a tumor-fighting response. In their experiments, they have already detected initial reactions to this activation, so they will delve further into this line of research in future work.

"Gene editing of amplification in tumors may be a basis for developing precision gene therapies for resistant cancers," the authors say.

They have also begun to explore the combination with existing therapies, always in animal models. By combining gene editing and one of the common drugs used in chemotherapy for neuroblastoma, they observed that the number of cells that died was larger than the sum of those caused by the two treatments separately.

Alejandro Nieto and Marta Martínez-Lage, the first authors of the study, state that "the study demonstrates a CRISPR-based novel strategy that turns oncogene amplification into a vulnerability, triggering the death only of the tumor cells, which could open up a pathway towards precision therapies for hard-to-treat tumors."

Publication details

A. Nieto-Sanchez et al, Selective genome editing of amplified oncogenes triggers immunogenic cell death and tumor remodeling, Molecular Cancer (2025). DOI: 10.1186/s12943-025-02542-0

Journal information: Molecular Cancer